Multiple reports say an experimental oral pill shows early signs of shrinking tumours in patients with several difficult-to-treat cancers. The coverage describes a small, early-stage trial in which the pill produced tumour shrinkage in a subset of patients across six cancer types that are described as hard to treat. One report states that tumours shrink by nearly a third in about a third of patients, though the specific measurement criteria, the trial size, and other outcome details are not provided in the excerpts. The reporting also frames the results as preliminary, noting that they come from an early trial rather than later-stage studies. The articles do not specify the pill’s name, the exact cancer types included, the dose, how long patients were followed, or whether the results were confirmed in independent studies. Overall, the sources agree that early trial data indicate measurable tumour reduction in some patients, and that further research is needed to verify effectiveness and assess safety and durability of response.
Early trial reports tumour shrinkage in some patients using experimental pill
Multiple reports say an experimental oral pill shows early signs of shrinking tumours in patients with several difficult-to-treat cancers. The coverage describes a small, early-stage trial in which th...
- An experimental pill is being tested in an early clinical trial for multiple difficult-to-treat cancers.
- Early results report tumour shrinkage in a subset of patients across six cancer types.
- One report says about a third of patients experience tumour reduction of nearly one-third.
- The results are described as preliminary and from early-stage testing.
- The provided excerpts do not include detailed trial design, cancer breakdown, or safety outcomes.
An experimental pill can shrink tumours by nearly a third in six of the world's most difficult to treat cancers, early trial results have found.
2 months agoAn experimental pill can shrink tumours by nearly a third in six of the world's most difficult to treat cancers, early trial results have found.
2 months ago
Procam launches “HDOR – 100 Days of Running” campaign to build daily running habits
Procam launches “HDOR – 100 Days of Running,” a new initiative framed around completing 100 days of movement to help par...
NMC publishes list of 52,690 PG medical students admitted for 2025-26 session
The National Medical Commission (NMC) has released an online list of 52,690 students admitted to postgraduate medical ed...
UK nationals, including NHS workers, missing after Nepal flash floods
A flash flood in Nepal caused widespread damage and leaves thousands missing, with reports stating that 33 UK citizens a...